Drug
SHR-9839
SHR-9839 is a pharmaceutical drug with 4 clinical trials. Currently 4 active trials ongoing.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
4(100%)
Phase Distribution
Ph phase_1
4
100%
Phase Distribution
4
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
4(100.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
4
trials recruiting
Total Trials
4
all time
Status Distribution
Active(4)
Detailed Status
Recruiting3
Active, not recruiting1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
4
Success Rate
N/A
Most Advanced
Phase 1
Trials by Phase
Phase 14 (100.0%)
Trials by Status
active_not_recruiting125%
recruiting375%
Recent Activity
4 active trials
Showing 4 of 4
recruitingphase_1
A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors
NCT06703177
active_not_recruitingphase_1
A Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
NCT06385678
recruitingphase_1
The Clinical Study of SHR-9839 for Injection in Patients With Advanced Solid Tumors
NCT05836948
recruitingphase_1
A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC
NCT06754930
Clinical Trials (4)
Showing 4 of 4 trials
NCT06703177Phase 1
A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors
NCT06385678Phase 1
A Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
NCT05836948Phase 1
The Clinical Study of SHR-9839 for Injection in Patients With Advanced Solid Tumors
NCT06754930Phase 1
A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4